Schering-Plough To Pay $165 Million To Shareholders For Clarinex Delay
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is settling claims it failed to reveal that negative FDA inspection reports would delay approval of its allergy medicine.
You may also be interested in...
Schering Puts Last Nail In Clarinex' Coffin
Settlement of final patent cases means that generics will launch on Jan. 1, 2012.
Schering Puts Last Nail In Clarinex' Coffin
Settlement of final patent cases means that generics will launch on Jan. 1, 2012.
Merck/Schering: The Next Wave Of Consolidation
News of Pfizer's takeover of Wyeth has hardly had time to sink in and already a second mega-merger is shaking up big pharma. This time Merck is the buyer; the company announced March 9 that it proposes to acquire its cardiovascular joint venture partner Schering-Plough in a deal valued at $41.1 billion